HRP20210025T1 - Farmaceutske kompozicije koje sadrže levodop, inhibitor dopaminske dekarboksilaze i komt inhibitor i metoda administracije istih - Google Patents
Farmaceutske kompozicije koje sadrže levodop, inhibitor dopaminske dekarboksilaze i komt inhibitor i metoda administracije istih Download PDFInfo
- Publication number
- HRP20210025T1 HRP20210025T1 HRP20210025TT HRP20210025T HRP20210025T1 HR P20210025 T1 HRP20210025 T1 HR P20210025T1 HR P20210025T T HRP20210025T T HR P20210025TT HR P20210025 T HRP20210025 T HR P20210025T HR P20210025 T1 HRP20210025 T1 HR P20210025T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- gel composition
- composition according
- komt
- levodopa
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims 22
- 229960003638 dopamine Drugs 0.000 title claims 11
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title claims 9
- 239000003954 decarboxylase inhibitor Substances 0.000 title claims 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims 8
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims 8
- 229960004502 levodopa Drugs 0.000 title claims 8
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 17
- 239000008252 pharmaceutical gel Substances 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 9
- 239000000499 gel Substances 0.000 claims 6
- 229960003337 entacapone Drugs 0.000 claims 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- HVGGGVAREUUJQV-CHHVJCJISA-N (4z)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-2h-1,2,4-oxadiazol-5-ylidene]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-one Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C(NO1)=N\C1=C\1C=C([N+]([O-])=O)C(=O)C(O)=C/1 HVGGGVAREUUJQV-CHHVJCJISA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 229960004205 carbidopa Drugs 0.000 claims 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229950001673 opicapone Drugs 0.000 claims 2
- 229960004603 tolcapone Drugs 0.000 claims 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229960001794 melevodopa Drugs 0.000 claims 1
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Farmaceutska gel kompozicija za intra-intestinalnu administraciju, koja sadrži agens za zamjenu dopamina izabran od levodopa, melevodopa, etilevodopa i njihovih kombinacija, inhibitor dopaminske dekarboksilaze (IDD) pri čemu je inhibitor dopaminske dekarboksilaze karbidopa, a katehol-O-metiltransferazni (KOMT) inhibitor izabran od entakapona, tolkapona, opikapona i njihovih kombinacija.
2. Farmaceutska gel kompozicija iz patentnog zahtjeva 1, pri čemu je levodop agens za zamjenu dopamina i poželjno pri čemu je maseni odnos KOMT inhibitora prema levodopu oko 10:1 do oko 2:1, ili 5:1 do 3:1.
3. Farmaceutska gel kompozicija prema patentnim zahtjevima 1-2, pri čemu entakapon je KOMT inhibitor.
4. Farmaceutska gel kompozicija prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu gel kompozicija ima pH vrijednost jednaku ili nižu od oko 5.7, poželjno od oko 4.5 do oko 5.5.
5. Farmaceutska gel kompozicija prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu gel kompozicija dalje sadrži antioksidans.
6. Farmaceutska gel kompozicija prema patentnom zahtjevu 5, pri čemu askorbinska kiselina ili limunska kiselina je antioksidans.
7. Farmaceutska gel kompozicija prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu su levodop, IDD i KOMT inhibitor u formi čestica;
čestice su suspendirane u vodenom nosaču, i imaju veličinu čestica ne veću od 80 µm; i nosač ima viskozitet od najmanje 300 mPas pri umjerenoj brzini smicanja.
8. Farmaceutska gel kompozicija prema patentnom zahtjevu 7, pri čemu je nosač polisaharid izabran iz grupe koja se sastoji od celuloze, metil celuloze, etil celuloze, karboksmetil celuloze, njihovih soli, i njihovih kombinacija.
9. Farmaceutska gel kompozicija prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu gel kompozicija sadrži oko 1.0 do oko 15 % (m/m) mikroniziranog levodopa, oko 0.1 do oko 2.0 % (m/m) mikroniziranog karbidopa, oko 1.0 do oko 5.0 % (m/m) mikroniziranog entakapona, i oko 1.0 do oko 7.5 % (m/m) natrij karboksmetil celuloze.
10. Farmaceutska gel kompozicija prema bilo kojem od patentnih zahtjeva 7 do 9, pri čemu je pH vrijednost gela veća od oko 5.0 i
viskozitet vodenog nosača nakon 12 dana na 25°C je najmanje oko 300 mPas pri umjerenoj brzini smicanja.
11. Farmaceutska gel kompozicija prema patentnom zahtjevu 2, pri čemu je maseni odnos inhibitora dopaminske dekarboksilaze naspram levodopa oko 1:10 do oko 1:2, ili oko 1:5 do oko 1:3.
12. Farmaceutska gel kompozicija prema patentnom zahtjevu 2, pri čemu kompozicija sadrži najmanje oko 10 mg/ml levodopa, najmanje oko 2.5 mg/ml inhibitora dopaminske dekarboksilaze, i najmanje oko 10 mg/ml KOMT inhibitora.
13. Farmaceutska gel kompozicija prema patentnom zahtjevu 1 za intra-intestinalnu administraciju koja sadrži levodopu, inhibitor dopaminske dekarboksilaze i KOMT inhibitor,
pri čemu je maseni odnos KOMT inhibitora naspram inhibitora dopaminske dekarboksilaze oko 10:1 do oko 2:1, ili oko 5:1 do oko 3:1.
14. Metoda za produžavanje roka trajanja farmaceutskog gela koja obuhvaća:
osiguravanje prvog gela koji sadrži levodop i inhibitor dopaminske dekarboksilaze; i
- uključivanje KOMT inhibitora u prvi gel; pri čemu karbidop je inhibitor dopaminske dekarboksilaze, a katehol-O-metiltransferazni (KOMT) inhibitor je izabran od entakapona, tolkapona, opikapona i njihovih kombinacija.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344 | 2015-03-24 | ||
| EP15838800.9A EP3188725B1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| PCT/SE2015/050939 WO2016036308A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210025T1 true HRP20210025T1 (hr) | 2021-03-05 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240314TT HRP20240314T1 (hr) | 2014-09-04 | 2015-09-04 | Farmaceutske gel kompozicije koje sadrže levodopu, karbidopu i entakapon |
| HRP20210025TT HRP20210025T1 (hr) | 2014-09-04 | 2021-01-07 | Farmaceutske kompozicije koje sadrže levodop, inhibitor dopaminske dekarboksilaze i komt inhibitor i metoda administracije istih |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240314TT HRP20240314T1 (hr) | 2014-09-04 | 2015-09-04 | Farmaceutske gel kompozicije koje sadrže levodopu, karbidopu i entakapon |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10071069B2 (hr) |
| EP (3) | EP3188725B1 (hr) |
| JP (2) | JP6622310B2 (hr) |
| CN (1) | CN107072973A (hr) |
| AU (3) | AU2015312430B2 (hr) |
| CA (2) | CA3175785A1 (hr) |
| DK (2) | DK3782617T3 (hr) |
| ES (2) | ES2973289T3 (hr) |
| FI (1) | FI3782617T3 (hr) |
| HR (2) | HRP20240314T1 (hr) |
| HU (2) | HUE052857T2 (hr) |
| PL (2) | PL3188725T3 (hr) |
| PT (2) | PT3782617T (hr) |
| RS (1) | RS65337B1 (hr) |
| SI (2) | SI3782617T1 (hr) |
| WO (1) | WO2016036308A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052857T2 (hu) | 2014-09-04 | 2021-05-28 | Lobsor Pharmaceuticals Ab | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
| WO2016083863A1 (en) * | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| AU2017250002B2 (en) | 2016-04-11 | 2022-12-22 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| WO2018017850A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| UA124124C2 (uk) | 2017-02-13 | 2021-07-21 | Баєр Енімал Хелс Гмбх | Рідка композиція, що містить прадофлоксацин |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| JP7485874B2 (ja) * | 2018-03-23 | 2024-05-17 | イントランス・メディカル・システムズ・インコーポレイテッド | 神経変性障害の治療のための医薬組成物の連続的投与 |
| EP3593819A1 (en) * | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| JP7506371B2 (ja) | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6376545B1 (en) * | 1998-11-10 | 2002-04-23 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing L-DOPA ethyl ester |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| US20050070608A1 (en) | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| UA95954C2 (ru) | 2006-05-31 | 2011-09-26 | Солвей Фармасьютикалс Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| WO2008053297A2 (en) | 2006-10-30 | 2008-05-08 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| RU2485947C2 (ru) * | 2008-02-06 | 2013-06-27 | Вокхардт Рисерч Сентер | Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью |
| MX364974B (es) * | 2009-05-19 | 2019-05-16 | Neuroderm Ltd | Composiciones para la administracion continua de inhibidores de dopa descarboxilasa. |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| ES2776734T3 (es) | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| CA2904838C (en) | 2013-03-13 | 2021-03-16 | Neuroderm Ltd. | Method for treatment of parkinson's disease |
| HUE052857T2 (hu) | 2014-09-04 | 2021-05-28 | Lobsor Pharmaceuticals Ab | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en active Application Filing
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2021
- 2021-01-07 HR HRP20210025TT patent/HRP20210025T1/hr unknown
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US20220362193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210025T1 (hr) | Farmaceutske kompozicije koje sadrže levodop, inhibitor dopaminske dekarboksilaze i komt inhibitor i metoda administracije istih | |
| JP2017527623A5 (hr) | ||
| HRP20201948T1 (hr) | Pripravci inhibitora dopa-dekarbokilaze | |
| HRP20200940T1 (hr) | Otopina za oralnu rehidraciju i njene metode | |
| MX2022007083A (es) | Composicion de espuma oral. | |
| HRP20170864T1 (hr) | Čvrsti dozni oblici s kontroliranim oslobađanjem | |
| JP2011525115A5 (hr) | ||
| RU2013154109A (ru) | Композиции, содержащие гидрогелевые частицы | |
| RS53121B (en) | PHARMACEUTICAL COMPOSITION OF POWERFUL HCV INHIBITOR FOR ORAL USE | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| JP2017507973A5 (hr) | ||
| RS54584B1 (en) | 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE | |
| RS54632B1 (en) | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING NITIZINON | |
| HRP20160406T1 (hr) | Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima | |
| WO2015171460A3 (en) | Formulations of cyclophosphamide liquid concentrate | |
| NZ620040A (en) | Formulations of deoxycholic acid and salts thereof | |
| BR112017026202A2 (pt) | composição modificadora da reologia seca, método de preparação da composição modificadora da reologia seca, formulação de produto e método de preparação de formulação | |
| NZ599377A (en) | Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| PH12014501981A1 (en) | Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them | |
| WO2019031898A3 (ko) | 약학 조성물 및 이의 제조방법 | |
| HRP20200504T1 (hr) | Lokalni preparati farmaceutskih i medicinskih proizvoda koji sadrže kombinacije sukralfata, hijaluronske kiseline, arginina i prirodnog hidratantnog sredstva | |
| BR112019000721A2 (pt) | formulação farmacêutica oral, e método de preparação de uma formulação farmacêutica oral | |
| IL304247A (en) | History of spirocyclohexane, pharmaceutical preparations containing them and their use as anti-apoptotic inhibitors | |
| HRP20211759T1 (hr) | Topikalna kompozicija koja sadrži kalcipotriol i betametazon dipropionat |